I prefer the 750 mg dose for almost all CAP patients because I can reduce the length of therapy and, therefore, reduce the total exposure to the antimicrobial agent. Also, from a theoretical point of view based on better pharmacodynamic parameters, as well as the results of clinical studies, I know that patients will experience more rapid symptom resolution when treated with 750 mg levofloxacin. This is certainly a benefit to the patient, and a cost saving to the health care system. In addition, I particularly like the higher dose if the patient has any of the known risk factors for more resistant pathogens and this higher dose gives me greater confidence that the pathogen will be eradicated and there will be less likelihood of subsequent emergence of resistance.I foresee that levofloxacin will be increasingly used as 750 mg once daily for 5 days short course therapy for the treatment of community acquired respiratory tract infections in the future.